Core Insights - Orthofix Medical Inc. (NASDAQ:OFIX) is recognized as one of the 12 most promising small-cap stocks by Wall Street analysts [1] - Canaccord has reduced its price target for OFIX from $24 to $20 while maintaining a Buy rating, following the company's fourth-quarter performance update and its outlook for 2026 [2] Financial Outlook - For 2026, Orthofix projects adjusted EBITDA to be between $95 million and $98 million, with expectations of positive free cash flow for the entire year, excluding any potential court settlement outcomes [3] - The company anticipates revenue contributions from the TRUELOK Elevate System, FITBONE Bone Transport, and Trochanteric Lengthening Nails, along with a full launch of VIRATA in the latter half of the year [4] Strategic Focus - Management emphasizes priorities for 2026, including enhancing commercial execution, increasing market penetration, and promoting the use of enabling technologies like 7D FLASH Navigation [3] - Other areas of concentration include simplifying the Spine commercial channel, expanding the Biologics offering, and maintaining development in Limb Reconstruction and BGT operations, which are expected to support consistent revenue growth and improved cash flow [4][5]